Castleman’s disease of the head and neck: a clinicopathologic study of 10 cases

Abstract

Abstract: PURPOSE: To summarize the clinicopathological features, diagnosis, treatment strategies and prognosis of Castleman's disease (CD) in the head and neck. METHODS: We analyzed 10 cases of CD in the head and neck region with pathological diagnosis of CD treated between January 1998 and September 2015. Immunohistochemical staining was performed on paraffin-embedded tissues. RESULTS: The studied subjects consisted of 6 males and 4 females. The median age was 44 years old(range from 19 to 67 years old). The course of disease ranged from 15 days to 8 years with a median of 12 months. The most common sign was an asymptomatic mass in head or neck region. The primary lesions included the parotid region in 3 patients and neck in 7 patients. According to histopathological subclassification, 6 cases were hyaline-vascular type (HVT) and 4 cases were plasma cell type (PCT). Clinically, 6 cases were localized HVT-CD, 2 cases were localized PCT-CD and 2 were multicentric CD. CONCLUSIONS: CD should be considered in the differential diagnosis of cervical nodal enlargements. Overgrowth of follicular dendritic cells in the hyaline vascular type of CD might represent a precursor of follicular dendritic cell sarcoma.

Key words: Castleman disease, Head and neck, Clinical pathology

CLC Number:

R739.8

CHEN Jia, ZHOU Jie, WANG Guo-dong, HUANG Jian-tao, CHEN Xiao-qing, WU Yang, LIU Yuan, JIANG Lei, ZHAO Yun-fu. Castleman’s disease of the head and neck: a clinicopathologic study of 10 cases[J]. China Journal of Oral and Maxillofacial Surgery, 2016, 14(3): 257-262.

References

[1] Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma [J]. Cancer, 1956, 9(4): 822-830.
[2] Rosai J. Rosai and Ackerman's surgical pathology 2 volume set (Rosai & Ackerman's surgical pathology) [M]. 9th Ed. St Louis: Mosby, 2004: 1905-1908.
[3] Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease [J]. Cancer Control, 2014, 21(4): 266-278.
[4] 钟来平, 王丽珍, 季彤, 等. 腮腺和颈部透明血管型Castleman病的临床分析 [J]. 中国口腔颌面外科杂志, 2009, 7(6): 500-504.
[5] Song JJ, Jung MH, Woo JS, et al. Castleman's disease of the head and neck [J]. Eur Arch Otorhinolaryngol, 2006, 263(2): 160-163.
[6] Melkundi RS, Prasad KC, Jalisatgi RR, et al. Unicentric castlemans disease: unusual disorder of the neck a case review [J]. J Clin Diagn Res, 2015, 9(4): MD03-MD04.
[7] Dong Y, Wang M, Nong L, et al. Clinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factor [J]. Br J Haematol, 2015, 169(6): 834-842.
[8] Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease [J]. Blood, 2014, 124(24):3544-3552.
[9] Frizzera G, Banks PM, Massarelli G, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients [J]. Am J Surg Pathol, 1983, 7(3): 211-231.
[10] Frizzera G, Peterson BA, Bayrd ED, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients [J]. J Clin Oncol, 1985, 3(9): 1202-1216.
[11] Joseph N, Vogelzang RL, Hidvegi D, et al. Computed tomography of retroperitoneal Castleman's disease (plasma cell type) with sonographic and angiographic correlation [J]. J Comput Assist Tomogr, 1985, 9(3): 570-572.
[12] Jiang L, Zhao LY, Liu Y, et al. Castleman's disease of the neck: report of 4 cases with unusual presentations [J]. J Oral Maxillofac Surg, 2011, 69(4): 1094-1099.
[13] Pauwels P, Dal Cin P, Vlasveld LT, et al. A chromosomal abnormality in hyaline vascular Castleman's disease: evidence for clonal proliferation of dysplastic stromal cells [J]. Am J Surg Pathol, 2000, 24(6): 882-888.
[14] Nguyen DT, Diamond LW, Hansmann ML, et al. Castleman's disease. Differences in follicular dendritic network in the hyaline vascular and plasma cell variants [J]. Histopathology, 1994, 24(5): 437-443.
[15] Monda L, Warnke R, Rosai J. A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation, a report of 4 cases [J]. Am J Pathol, 1986, 122(3): 562-572.
[16] Chan JK, Fletcher CD, Nayler SJ, et al. Follicular dendritic cell sarcoma. Clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized [J]. Cancer, 1997, 79(2): 294-313.
[17] Lin O, Frizzera G. Angiomyoid and follicular dendritic cell proliferative lesions in Castleman's disease of hyaline-vascular type: a study of 10 cases [J]. Am J Surg Pathol, 1997, 21(11): 1295-1306.
[18] Yi AY, de Tar M, Becker TS, et al. Giant lymph node hyperplasia of the head and neck (Castleman's disease): a report of five cases [J]. Otolaryngol Head Neck Surg, 1995, 113(4): 462-466.
[19] Puram SV, Hasserjian RP, Faquin WC, et al. Castleman disease presenting in the neck: report of a case and review of the literature [J]. Am J Otolaryngol, 2013, 34(3): 239-244.
[20] Uysal B, Demiral S, Gamsiz H, et al. Castleman's disease and radiotherapy: a single center experience [J]. J Cancer Res Ther, 2015, 11(1): 170-173.
[21] Eszes N, Tamási L, Csekeö A, et al. Unicentric mixed variant Castleman disease associated with intrabronchial plasmacytoma [J]. Diagn Pathol, 2014, 20(9): 64-69.
[22] Jung CP, Emmerich B, Goebel FD, et al. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide [J]. Am J Hematol, 2004, 75(3): 176-177.
[23] Lin Q, Fang B, Huang H, et al. Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease [J]. Blood Cancer J, 2015, 5: e298.
[24] Ho LJ, Luo SF, Lai JH. Biological effects of interleukin-6: clinical applications in autoimmune diseases and cancers [J]. Biochem Pharmacol, 2015, 97(1): 16-26.